-
Shaanxi Governor Zhao Yide met with representatives of Qin Shang, chairman of Ted Pharmaceuticals, Zheng Xiangling
Time of Update: 2021-01-11
Zheng Xiangling said that the vast number of Qin merchants will give full play to their own advantages, vigorously carry forward the spirit of qin business in the new era, warm return to the hometown father old, share social responsibility, for Shaanxi's economic and social development to make greater contributions.
-
Ted Pharmaceuticals Chairman Zheng Xiangling was honored as the 2020 Pharmaceutical Industry Pioneer of the Year Ted
Time of Update: 2021-01-11
, Ted Pharmaceuticals Chairman Zheng Xiangling was named the 2020 Pharmaceutical Industry Pioneer of the Year, and Ted Pharmaceuticals was named the best employer in the pharmaceutical industry in 2020.
-
Dongsian benzoic acid agritin tablets received a drug registration certificate approved by NMPA
Time of Update: 2021-01-11
the product is one of 27 generic drug Aglitin tablets purchased by Yichang Dong Sunshine Changjiang Pharmaceutical Co., Ltd., a controlling subsidiary of the company, from its affiliate Guangdong Dongsian Pharmaceutical Co., Ltd. in 2019 at a transaction price of 6.6262 million yuan.
-
Risk of microbial contamination Mercedon recalls 6 batches of sterile drugs
Time of Update: 2021-01-11
Recently, the MHRA, the UK's drug regulator, issued two drug recall notices: Mercadon recalled its compound antibiotic product Zerbaxa for microbial contamination, involving multiple batches, and Fessenyuscabi recalled 0.9% sodium chloride injections because some products were labeled Polish.
-
Which companies in the biopharmaceutical M.A. market deserve attention in 2021?
Time of Update: 2021-01-11
the product in its research, RGX-314, is a gene therapy for the treatment of wet age macular degeneration, using AAV carriers to carry genetically modified proteins that can neutralize VEGF activity, and is currently in phase 1/2a clinical trials, which is expected to bring a new therapeutic experience to the patients involved.
-
2020 Karelli Pearl Single Resistance Summary Report
Time of Update: 2021-01-11
November, professor Wang Jie led the PASSION study, published in Journal of Thoracic Oncology, which provides new evidence of immune co-targeting (Carelli's beadone and apatinib) for the second-line treatment of broad-stage small cell lung cancer5.
-
Xinda BioAdam single anti-injection fluid has been approved by NMPA for two new adaptations
Time of Update: 2021-01-11
On December 23, Xinda Bio announced that its recombinant human anti-tumor necrotic cause - α (TNF-α) monoclonal antibody drug Surisin ® (Adamo monoantigen injection, English trademark: SULINNO®) was obtained NMPA approved two new adaptations for the treatment of plaque-like psoriasis in children and inadequate response to glucosal hormones, the need for the use of glucoticoids in moderation, or non-infectious intermediate glucitis, post-glucitis, and whole glucitis in adults who are not suitable for glucosticosteroid therapy.
-
Ano Pharma and Roche will conduct clinical trials with PD-L1 monoantigen "T-drugs"
Time of Update: 2021-01-11
On December 4, 2020, Adlai Nortye Pharmaceuticals, a global biopharmaceutical company focused on oncology immunotherapy, announced a clinical cooperation agreement with Roche Pharmaceuticals, which w
-
Adamo monobial-like drug Handa is ® in China
Time of Update: 2021-01-11
On December 26, 2020, Wanbang Pharma, a subsidiary of Shanghai Fosun Pharma (Group) Co., Ltd., officially announced that the Adamo single anti-injection (commodity name: Handayuan®) developed and pro
-
The six pharmaceutical companies will cease listing in 2020
Time of Update: 2021-01-11
Company's "fifth set of standards" of the listing application was accepted by the Shanghai Stock Exchange on June 23, 2020, its original plan to raise 1.316 billion yuan, mainly for drug research and development projects and marketing network construction projects.
-
The controlling shareholder of Daan Gene changed the company's real controller to the Guangzhou municipal government
Time of Update: 2021-01-11
According to the latest industrial and commercial registration information of the controlling shareholder, Guangzhou Zhongda Holdings Co., Ltd., its shareholders were changed from Zhongshan University to Guangzhou Financial Holding Group Co., Ltd., resulting in the change of the actual controller of the Company from Zhongshan University to the Guangzhou Municipal People's Government, and the controlling shareholder of the company remained unchanged and remained the controlling shareholder of The Company.
-
Injection once a week! Noro and NORD long-acting human growth hormone have been approved clinically in China
Time of Update: 2021-01-11
On December 22, the website of the Drug Review Center (CDE) of China's State Drug Administration announced that Novo Nordisk's Class 1 bio-new drug somapacitan injections had been approved by clinical trials to treat children with slow growth due to insufficient endogenous growth hormone secretion.
-
Thousands of calls began to come out, Karelli Zhu single resistance successfully entered the new version of the national health insurance directory
Time of Update: 2021-01-11
And from the medical insurance published reimbursable adaptive disorders, Karelli pearl single anti is the only lung cancer, liver cancer, esophageal cancer patients to enjoy the health insurance reimbursement policy PD-1 single resistance, other PD-1 drugs are not available for reimbursement of the three major cancers.
-
Lingbei antidepressants in crisis again? Yangzijiang and other 6 to grab the first imitation
Time of Update: 2021-01-10
source: MED2.0 China Drug Review Database Prior to this, Yangzijiang Pharmaceuticals, Zhengda Tianqing Pharmaceutical Group, Jiangsu Haussen Pharmaceuticals, Chengdu Bett Pharmaceuticals and other 5 enterprises have submitted applications for listing, in the review and approval (in the drug review center).
-
East China will take $2 billion in oral anti-sugar drugs and East Sunshine drugs to siege Merca East
Time of Update: 2021-01-09
Medicine Network November 17th, recently, NMPA official website data show that china and eastern China's Sigletin metformin tablets (I.) class 4 imitation listing applications into the "in the approval" state, is expected to usher in good news in the near future.
-
6 billion PPI injections! East China Medicine has been evaluated
Time of Update: 2021-01-09
Medicine Network November 18th, November 17th, the official website of the State Drug Administration shows that Hangzhou Sino-American East China Pharmaceutical injection of sodium totrazolatin through a consistent evaluation of supplementary applications.
-
Sichuan pharmaceutical company hits the first company with 2 billion large varieties
Time of Update: 2021-01-09
Figure 3:2020H1 osteosterol enterprise competition pattern source: Mi net China's public medical institutions terminal competition pattern market domestic osteotisanol only Zhengda Pharmaceutical (Qingdao) was approved, the product is softgels, the enterprise also submitted a consistent evaluation of supplementary applications in July this year, is currently in review and approval.
-
GE Healthcare and China Pharmaceutical Group announced a 30-year alliance
Time of Update: 2021-01-08
"GE Healthcare and China Pharmaceuticals have been deeply cooperative, including in the field of domestic high-end medical equipment manufacturing, in the next 30 years, we hope to continue to integrate global resources with domestic resources, National Pharmaceuticals in all aspects of operation, channels, production has advantages, we will continue to promote a comprehensive domestic strategy." how do we define localization and what are the aspects?
-
East Sunshine Medicine took 1.5 billion varieties of 24 new products on the way
Time of Update: 2021-01-08
tu: Tigrello film evaluation source: Mi net consistency evaluation database including East Sunshine medicine, there are currently 9 domestic enterprises for Grelo tablets approved production and as reviewed, including Yangzijiang, Zhengda Tianqing, Xinlitai, stone medicine and so on.
-
It's going to take 3.5 billion image agent varieties
Time of Update: 2021-01-07
Iodine kesal injections to be approved enterprise source: Mi net one-click retrieval of minenet data show that Harbin Triple Pharmaceuticals according to imitation 6 categories of submitted iodized keshaol injection application in the review and approval; source: MiNet Database, NMPA
